FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549	
-------------	------------	--

Check this box if no longer subject
to Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* INGRAM ROBERT ALEXANDER						2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICALS INC									Relationship of Reporting Person(s) to Issuer (Check all applicable)						
INGRAM ROBERT ALEXANDER					lΓBO	[BCRX]								X	Direc	tor		10% O	wner		
(Last) (First) (Middle)						[BOICK]									Office belov	er (give title v)		Other (below)	specify		
280 S. MANGUM STREET						3. Date of Earliest Transaction (Month/Day/Year)															
SUITE 350																					
						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)							
(Street)					1									X	Form	filed by On	e Rep	ortina Pers	on		
DURHA	M NO	2	7701												Form filed by More than One Reporting						
(City)	(C+	oto) (7	7: _~ \												Perso	on					
(City)	(Sta	ate) (2	Zip)																		
		Table	I - No	n-Deriva	tive S	Secu	rities	Acq	uired,	Dis	posed of	, or E	Benefi	cially	/ Own	ed					
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day			Execution D //Year) if any			ution Date,		3. Transaction Code (Instr. 8) 4. Securion Disposed 5)				4 and Securi Benefi Owned		ties cially Following	Form (D) o	wnership n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership				
										v	Amount	(A) or (D) Pr		ce	Transa	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)		
Common Stock ⁽¹⁾ 08/31/2				2021				A		1,177	A	\$1	5.92	77,378			D				
		Tal									osed of,				Owne	d					
				(e.g., pu	its, ca	alls, v	warra	ants,	optio	ns, c	onvertib	le se	curitie	es)							
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	emed ion Date, /Day/Year)		Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercis. Expiration Date (Month/Day/Yea		7. Titl Amou Secur Under Derive Secur 3 and	int of rities rlying ative rity (Inst	De Sec (Ins	Price of rivative curity str. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amour or Number of Shares	er							

Explanation of Responses:

 $1. \ Shares of \ Common \ Stock \ is sued to the \ reporting \ person \ in \ lieu \ of \ quarterly \ cash \ Board \ Member \ retainer \ of \$18,750.$

/s/ Alane P. Barnes, by power of attorney

09/02/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.